In vitro chemosensitivity to gemcitabine, oxaliplatin and zoledronic acid predicts treatment response in metastatic gastric cancer

Anti-Cancer Drugs

Volumn 16, Issue 1, 2005, Pages 87-91

  Trojan, Jörg ^a   Kim, Soo Zin ^a   Engels, Knut ^a   Kriener, Susanne ^a   Mitrou, Paris S ^a   Chow, Kai U ^a  

^a UNIVERSITY HOSPITAL FRANKFURT   (Germany)

Author keywords

Apoptosis; Combination chemotherapy; In vitro chemosensitivity; Signet ring cell carcinoma; Stomach neoplasm

Indexed keywords

CISPLATIN; DOXORUBICIN; FLUOROURACIL; FOLINIC ACID; GEMCITABINE; OXALIPLATIN; ZOLEDRONIC ACID;

AGED; APOPTOSIS; ARTICLE; BONE MARROW BIOPSY; CANCER CELL CULTURE; CANCER COMBINATION CHEMOTHERAPY; CASE REPORT; CELL INFILTRATION; CHEMOSENSITIVITY; CLINICAL FEATURE; DIAGNOSTIC IMAGING; DISEASE COURSE; DISSEMINATED INTRAVASCULAR CLOTTING; DRUG POTENTIATION; DRUG RESPONSE; HUMAN; HUMAN TISSUE; IN VITRO STUDY; LABORATORY TEST; MALE; METASTASIS; NAUSEA; PERIPHERAL NEUROPATHY; PRIORITY JOURNAL; SIGNET RING CARCINOMA; STOMACH CANCER; TUMOR CELL;

AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, SIGNET RING CELL; DEOXYCYTIDINE; DIPHOSPHONATES; DRUG SCREENING ASSAYS, ANTITUMOR; HUMANS; IMIDAZOLES; MALE; NEOPLASM STAGING; ORGANOPLATINUM COMPOUNDS; PREDICTIVE VALUE OF TESTS; REMISSION INDUCTION; STOMACH NEOPLASMS; TUMOR CELLS, CULTURED;

EID: 12544249761     PISSN: 09594973     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001813-200501000-00013     Document Type: Article

References (12)

1. Hohenberger P, Gretschel S. Gastric cancer. Lancet 2003; 362:305-315.
2. Etoh T, Baba H, Taketomi A, Nakashima H, Kohnoe S, Seo Y, et al. Diffuse bone metastasis with hematologic disorders from gastric cancer: clinicopathological features and prognosis. Oncol Rep 1999; 6:601-605.
3. Chow KU, Boehrer S, Geduldig K, Krapohl A, Hoelzer D, Mitrou PS, et al. In vitro induction of apoptosis of neoplastic cells in low-grade non-Hodgkin's lymphomas using combinations of established cytotoxic drugs with bendamustine. Haematologica 2001; 86:485-493.
4. Chow KU, Sommerlad WD, Boehrer S, Schneider B, Seipelt G, Rummel MJ, et al. Anti-CD20 antibody (IDEC-C2B8, rituximab) enhances efficacy of cytotoxic drugs on neoplastic lymphocytes in vitro: role of cytokines, complement, and caspases. Haematologica 2002; 87:33-43.
5. Chow KU, Nowak D, Boehrer S, Ruthardt M, Knau A, Hoelzer D, et al. Synergistic effects of chemotherapeutic drugs in lymphoma cells are associated with down-regulation of inhibitor of apoptosis proteins (IAPs), prostate-apoptosis-response-gene 4 (Par-4), death-associated protein (Daxx) and with enforced caspase activation. Biochem Pharmacol 2003; 66:711-724.
6. Kim R, Emi M, Tanabe K, Uchida Y, Toge T. Chemosensitivity testing for gastrointestinal cancer: survival benefit potential and limitations. Anticancer Drugs 2003; 14:715-723.
7. Andreotti PE, Cree IA, Kurbacher CM, Hartmann DM, Linder D, Harel G, et al. Chemosensitivity testing of human tumors using a microplate adenosine triphosphate luminescence assay: clinical correlation for cisplatin resistance of ovarian carcinoma. Cancer Res 1995; 55:5276-5282.
8. Mercer SJ, Somers SS, Knight LA, Whitehouse PA, Sharma S, Di Nicolantonio F, et al. Portsmouth Upper GI Cancer Multi-Disciplinary Team. Heterogeneity of Chemosensitivity of esophageal and gastric carcinoma. Anticancer Drugs 2003; 14:397-403.
9. Louvet C, Andre T, Lledo G, Hammel P, Bleiberg H, Bouleuc C, et al. Gemcitabine combined with oxaliplatin in advanced pancreatic adenocarcinoma: final results of a GERCOR multicenter phase II study. J Clin Oncol 2002; 20:1512-1518.
10. Faivre S, Raymond E, Woynarowski JM, Cvitkovic E. Supraadditive effect of 2′,2′-difluorodeoxycytidine (gemcitabine) in combination with oxaliplatin in human cancer cell lines. Cancer Chemother Pharmacol 1999; 44:117-123.
11. Tempero M, Plunkett W, Ruiz Van Haperen V, Hainsworth J, Hochster H, Lenzi R, et al. Randomized phase II comparison of dose-intense gemcitabine: thirty-minute infusion and fixed dose rate infusion in patients with pancreatic adenocarcinoma. J Clin Oncol 2003; 21:3402-3408.
12. Corey E, Brown LG, Quinn JE, Poot M, Roudier MP, Higano CS, et al. Zoledronic acid exhibits inhibitory effects on osteoblastic and osteolytic metastases of prostate cancer. Clin Cancer Res 2003; 9:295-306.